CIS
RARE icon

Capital International Sarl’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital International Sarl’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,565
Closed -$810K – 211
2022
Q3 		$810K Buy
19,565
+2,035
+12% +$105K 0.07% 193
2022
Q2 		$1.05M Buy
17,530
+1,446
+9% +$89K 0.08% 185
2022
Q1 		$1.17M Sell
16,084
-18,722
-54% -$1.3M 0.06% 222
2021
Q4 		$2.93M Buy
34,806
+25,930
+292% +$2.11M 0.14% 158
2021
Q3 		$801K Sell
8,876
-1,349
-13% -$122K 0.07% 181
2021
Q2 		$975K Sell
10,225
-109
-1% -$11.4K 0.08% 177
2021
Q1 		$1.18M Sell
10,334
-1,608
-13% -$219K 0.11% 161
2020
Q4 		$1.65M Buy
11,942
+730
+7% +$86.6K 0.17% 125
2020
Q3 		$922K Buy
11,212
+463
+4% +$38.4K 0.11% 146
2020
Q2 		$841K Buy
10,749
+1,659
+18% +$110K 0.11% 149
2020
Q1 		$404K Sell
9,090
-32,159
-78% -$1.67M 0.07% 155
2019
Q4 		$1.76M Buy
41,249
+4,049
+11% +$167K 0.27% 101
2019
Q3 		$1.59M Sell
37,200
-14,800
-28% -$804K 0.27% 102
2019
Q2 		$3.3M Sell
52,000
-21,300
-29% -$1.36M 0.46% 68
2019
Q1 		$5.08M Buy
73,300
+2,200
+3% +$126K 0.64% 52
2018
Q4 		$3.09M Sell
71,100
-11,900
-14% -$650K 0.37% 82
2018
Q3 		$6.34M Buy
83,000
+17,100
+26% +$1.39M 0.6% 54
2018
Q2 		$5.07M Sell
65,900
-40,950
-38% -$2.64M 0.51% 57
2018
Q1 		$5.45M Hold
106,850
– – 0.52% 56
2017
Q4 		$4.96M Sell
106,850
-21,470
-17% -$1.05M 0.46% 62
2017
Q3 		$6.83M Buy
128,320
+4,000
+3% +$237K 0.57% 58
2017
Q2 		$7.72M Buy
124,320
+16,870
+16% +$1.02M 0.67% 49
2017
Q1 		$7.28M Buy
107,450
+16,700
+18% +$1.27M 0.63% 52
2016
Q4 		$6.38M Buy
90,750
+5,500
+6% +$390K 0.59% 58
2016
Q3 		$6.05M Buy
+85,250
New +$5.44M 0.51% 66

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Capital International Sarl's RARE Position: Q4 2022 in Review

Capital International Sarl sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 19,565 shares — an estimated $810K sold.

Capital International Sarl first reported a position in RARE in Q3 2016 and held it in 25 quarters. The position peaked at $7.72M in Q2 2017. 228 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Capital International Sarl reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Capital International Sarl sold 19,565 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $810K.
  • Capital International Sarl first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 25 quarters.
  • Capital International Sarl's Ultragenyx Pharmaceutical position peaked at $7.72M in Q2 2017.
  • 228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Capital International Sarl's 13F filing for Q4 2022, filed 14 Feb 2023.